Clinical Trial

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2017-05-29; most recent amendment 2025-11-04.
Status change: Recruiting → Active, Not Recruiting 2024-01-11
Status change: Not Yet Recruiting → Recruiting 2017-07-18
Trial Details
NCT Number NCT03173976
Lead Sponsor Mohammed Milhem
Collaborators: Rising Tide Foundation
Conditions Chondrosarcoma
Enrollment 17 participants
Start Date 2017-07-18
Primary Completion 2023-04-20 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-06